Shares of Prima BioMed Ltd. (NASDAQ:PBMD) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.

Analysts have set a 1 year consensus target price of $5.00 for the company, according to Zacks. Zacks has also assigned Prima BioMed an industry rank of 92 out of 265 based on the ratings given to its competitors.

Several analysts recently weighed in on the company. Zacks Investment Research downgraded Prima BioMed from a “hold” rating to a “sell” rating in a research note on Tuesday. FBR & Co reiterated an “outperform” rating and issued a $6.00 price objective on shares of Prima BioMed in a research report on Wednesday, June 15th. HC Wainwright reiterated a “buy” rating on shares of Prima BioMed in a research report on Wednesday, June 22nd. Roth Capital reiterated a “buy” rating and issued a $6.00 price objective on shares of Prima BioMed in a research report on Friday, August 26th. Finally, Maxim Group reiterated a “buy” rating on shares of Prima BioMed in a research report on Wednesday, June 22nd.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/zacks-analysts-set-5-00-target-price-for-prima-biomed-ltd-nasdaqpbmd.html

Shares of Prima BioMed (NASDAQ:PBMD) traded up 0.6748% on Tuesday, reaching $0.8951. The company’s stock had a trading volume of 32,078 shares. The stock has a 50-day moving average of $0.87 and a 200 day moving average of $0.95. The stock’s market capitalization is $61.51 million. Prima BioMed has a 52 week low of $0.72 and a 52 week high of $1.54.

Prima BioMed Company Profile

Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company’s main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response.

5 Day Chart for NASDAQ:PBMD

Get a free copy of the Zacks research report on Prima BioMed (PBMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Prima BioMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.